Oligodendroglioma: Clinical Presentation, Pathology, Molecular Biology, Imaging, and Treatment features the latest "cutting-edge" molecular biology, molecular therapeutics, imaging, immunotherapy, and research methods on the topic of oligodendrogliomas. The most detailed and comprehensive resource on the subject, it provides up-to-date information on clinical presentation, pathology, molecular biology, and treatment methods, including immunotherapy. This book is a critical for students, physicians and researchers in the fields of neuroscience, neuro-oncology, neurosurgery, radiation oncology, medical oncology, and others working in research or with patients.

Principles of Tumors: A Translational Approach to Foundations, Second Edition, provides a concise summary of translational/interdisciplinary topics on the various aspects of tumors, especially abnormalities in their cells, their causes and effects on patients. Topics discussed include how genomic abnormalities in tumors may result from the actions of carcinogens and how genomic changes determine the cell biological/morphological abnormalities in tumor cell populations. In addition, the relationships between tumor cell genomics and therapeutic outcomes are described. There are also supporting appendices on general bioscience, including the principles of histology (the cells and tissues of the body), genetics, pathology, radiology and pharmacology. This book gives a thorough, detailed, yet concise account of the main bioscience, clinical and therapeutic aspects of tumors. It emphasizes the translational aspects of research into tumors with extensive discussions of interdisciplinary issues. The content in this book will be invaluable for researchers and clinicians involved in collaborative projects where it is necessary to understand fundamental issues in other branches of biomedicine.

Once a certain death sentence and often a cause for shame, cancer is now a treatable disease. "Cancer" provides a broad introduction to this complex family of diseases, tracing the fascinating history of scientific discoveries that led to today's sophisticated treatments.

This extraordinary new volume, coauthored by three leaders in cancer research and surgery at Harvard Medical School, uses scientifically accurate yet accessible language to give readers a firm grounding in such essential concepts as angiogenesis and the genetics of cancer. In addition to information about types of cancer, diagnosis, and treatment, "Cancer" places special emphasis on new frontiers in research, psychological aspects of a cancer diagnosis, and quality-of-life issues for those living with disease. Useful features include a comprehensive glossary, a timeline of milestones in cancer research, and an appendix for students on how to pursue a career in science or medicine.

Nasopharyngeal Carcinoma: From Etiology to Clinical Practice discusses NPC from basic science, to clinical management through the perspective of members of the Centre for Nasopharyngeal Carcinoma Research in Hong Kong. It encompasses not only the most detailed information about multiple aspects of NPC, but also the modern day research model of scientist-clinician collaboration, focusing on bench-to-bedside approach. Basic science is covered, discussing genetics and genomics in NPC and its epidemiology and the role of Epstein-Barr Virus (EBV). Translational research is also covered, presenting topics such as animal models, plasma EBV DNA, molecular imaging and immunotherapy, amongst other topics. This book is a valuable source for cancer researchers, oncologists, medical oncologists and several members of the biomedical field who are interested in learning more about NPC management from both clinical and research perspectives.

miRNAs are a class of endogenous, small non-protein coding RNA molecules (~ 22 nucleotides) which are novel post-transcriptional regulators of gene expression. Since we have hundreds of miRNAs, the major challenge is now to understand their specific biological function. In fact the experimental evidence suggests that signaling pathways could be ideal candidates for miRNA-mediated regulation. Several studies suggest that miRNAs affect the responsiveness of cells to signaling molecules such as WNT, Notch, TGF- and EGFR. Altered expression of particular miRNAs has been implicated in the onset and development of cancer and could be used as potential biomarkers for the disease. Recently, many studies have found miRNAs have crucial regulatory roles in Cancer stem cells (CSCs) a kind of tumor initiating cells (TICs) and dormancy. Findings also suggest that DNA methylation may be important in regulating the expression of many miRNAs in several cancer initiating cells. Several miRNAs are known to either upregulated or downregulated in CSCs when compared to non-cancerous cells from the same tissues. CSCs are a small subpopulation of cells identified in a variety of tumors and involve in self-renewal, differentiation, chemoresistance and tumorigenesis. The volume will give a comprehensive account of important advancements in the area of miRNAs and cancer.

Soft cover, full colour photographs and illustrations

YOU HAVE CANCER or have a loved one who has been diagnosed with cancer! Your blood runs cold when you hear the diagnosis. After the shock and denial come the questions: What will I have to go through now? What are my chances?
What cancer is and how it originates
How common it is and success of cancer therapies
The importance of diet, regular examinations and self examination
The many branches and approaches of modern therapy
Modern treatment and prognosis of common cancers (29 types)
Breakthroughs in molecular biology with fewer side-effects
Bone marrow stem cell transplantation
edian survival periods
Alternative, complementary and integrated therapies
Patient support, recovery after mastectomy, cancer in youth and children, effective pain control, care of patients with advanced cancer
Support by community organisations
Author's personal perspective on suffering and healing through faith

Get a quick, expert overview of the latest treatment and management approaches for adenocarcinoma of the lung, including novel therapeutics in immunotherapy and targeted therapies. This practical title, edited by Dr. Leora Horn, offers succinct coverage of clinically-focused topics and guidelines, making it an ideal resource for practicing and trainee oncologists and other members of the cancer care team. Discusses surgical approaches, molecular testing, adjuvant therapy, first- and second-line therapy, and much more. Helps you translate current research and literature into practical information for daily practice. Consolidates today's available information on this timely topic into one convenient resource.

Androgens are critical regulators of prostate differentiation and function, as well as prostate cancer growth and survival. Therefore, androgen ablation is the preferred systemic treatment for disseminated prostate cancer. Androgen action is exerted in target tissues via binding the androgen receptor (AR), a nuclear receptor transcription factor.

Historically, the gene expression program mediated by the AR has been poorly understood. However, recent gene expression profiling and more traditional single-gene characterization studies have revealed many androgen-regulated genes that are important mediators of androgen action in both normal and malignant prostate tissue. This book will focus on the androgen-regulated gene expression program, and examine how recently identified androgen-regulated genes are likely to contribute to the development and progression of prostate cancer. Recent studies that have attempted to unravel how these genes are deregulated in androgen depletion independent prostate cancer will be included

This issue of Hematology/Oncology Clinics, edited by Dr. Ursula Matulonis, will focus on Ovarian Cancer. Topics include, but are not limited to, Risk factors for ovarian carcinoma; Ovarian cancer pathology; Early detection and prevention strategies for ovarian cancer; Pathogenesis, genetics and genomics of high grade serous cancer; Pathogenesis, genetics and genomics of non-high grade serous cancers; Management and Treatment of newly diagnosed ovarian cancer; Management and Treatment of recurrent ovarian cancer; Treatment of rare epithelial ovarian tumors; Targeting DNA damage response and repair as a therapeutic strategy for ovarian cancer; Mechanisms of drug resistance in ovarian cancer; The status of and targeting the immune system in ovarian cancer: current and future approaches; Antibody drug conjugates; The role of angiogenesis in ovarian cancer pathogenesis and treatment; Management and understanding of acute and long term toxicities of patients with ovarian cancer; and Palliative Care of the advanced ovarian cancer patient.

Viruses are the agent responsible for perhaps up to one million cases of cancer worldwide each year. Significantly, the study of viruses has also provided important clues to the causes and development of the most common human cancers. This volume presents an account of those viruses which have been directly associated with common human malignancies such as human papillomavirus (HPV), cervical carcinoma, Epstein-Barr virus (EBV) and Burkitt's lymphoma. In addition, the biology and biochemistry of those viruses which have been shown to be capable of transforming cells in culture are described in detail. Thus adenovirus are discussed, as are the other small DNA tumour viruses - Simian virus 40 (SV40) and polyoma virus. Consideration has also been given to human T-cell leukaemia virus (HTLV), hepatitis B virus (HBV) and human herpes virus 8 (HHV8), amongst others. General themes such as the host's immune response to viral infection, virally-induced apoptosis and the use of viruses as a delivery system in gene therapy have been discussed.
Individual chapters have been written by an international group of experts in their own field of research.

Get a quick, expert overview of the latest clinical information and guidelines for cancer checkpoint inhibitors and their implications for specific types of cancers. This practical title by Drs. Fumito Ito and Marc Ernstoff synthesizes the most up-to-date research and clinical guidance available on immune checkpoint inhibitors and presents this information in a compact, easy-to-digest resource. It's an ideal concise reference for trainee and practicing medical oncologists, as well as those in research. Discusses the current understanding of how to best harness the immune system against different types of cancer at various stages. Helps you translate current research and literature into practical information for daily practice. Presents information logically organized by disease site. Covers tumor immunology and biology; toxicities associated with immune checkpoint inhibitors; and future outlooks. Consolidates today's available information on this timely topic into one convenient resource.

This book presents an overview of antimicrobial peptides (AMPs), their mechanisms of antimicrobial action, other activities, and various problems that must still be overcome regarding their clinical application. Divided into four major parts, the book begins with a general overview of AMPs (Part I), and subsequently discusses the various mechanisms of antimicrobial action and methods for researching them (Part 2). It then addresses a range of activities other than antimicrobial action, such as cell penetration, antisepsis, anticancer, and immunomodulatory activities (Part 3), and explores the prospects of clinical application from various standpoints such as the selective toxicity, design, and discovery of AMPs (Part 4). A huge number of AMPs have been discovered in plants, insects, and vertebrates including humans, and constitute host defense systems against invading pathogenic microorganisms. Consequently, many attempts have been made to utilize AMPs as antibiotics. AMPs could help to solve the urgent problem of drug-resistant bacteria, and are also promising with regard to sepsis and cancer therapy. Gathering a wealth of information, this book will be a bible for all those seeking to develop antibiotics, anti-sepsis, or anticancer agents based on AMPs.